← Human Trials & Peer-Reviewed Studies
The effects of glucose-dependent insulinotropic polypeptide on net splanchnic blood flow in lean humans
Plain-language guide to PMID 41782271 (2026): crossover randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide).
Key Facts
- PMID
- 41782271
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Asmar M et al. (4 authors)
- DOI
- 10.1210/clinem/dgag084
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.
The aim of this study was to examine the effects of GIP on SBF, both independently and in combination with hyperglycemia and hyperinsulinemia.
Why It Was Studied
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone with potent vasoactive and metabolic effects in adipose tissue, but its effects on splanchnic blood flow (SBF) in humans remain unclear.
Investigating potential regional differences is important for understanding the vascular actions of GIP in humans.
Who Took Part
The age groups tagged for this paper are young adults and adults, men only.
In a randomized, controlled crossover study, 8 healthy, lean male participants underwent 4 separate experimental conditions.
How the Study Was Run
The researchers set it up as a randomized and crossover study.
Random assignment meant chance, not the researchers, decided who got GIP (Gastric Inhibitory Polypeptide) and who got the comparison, which limits bias.
Each person switched between GIP (Gastric Inhibitory Polypeptide) and the comparison at some point, usually with a gap in between.
Splanchnic blood flow was measured by Fick's Principle after catheterization of a hepatic vein, using indocyanine green as indicator.
What Was Measured
PubMed files the paper under topics including Gastric Inhibitory Polypeptide, Splanchnic Circulation, Glucose Clamp Technique, Hyperinsulinism, Hyperglycemia, Blood Glucose and Incretins.
The authors tagged it with the keywords blood flow, glucose-dependent insulinotropic polypeptide, incretin hormone, lean humans and liver.
What This Means in Plain Language
The paper is a randomized and crossover study of GIP (Gastric Inhibitory Polypeptide).
Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2026 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.